Shenzhen Kangtai Biological Products Co Ltd (300601) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Kangtai Biological Products Co Ltd (300601) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥405.44 Million ≈ $59.33 Million USD) by net assets (CN¥9.61 Billion ≈ $1.41 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shenzhen Kangtai Biological Products Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shenzhen Kangtai Biological Products Co balance sheet liabilities for a breakdown of total debt and financial obligations.
Shenzhen Kangtai Biological Products Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Kangtai Biological Products Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
0.045x |
|
Asahi India Glass Limited
NSE:ASAHIINDIA
|
0.038x |
|
DRDGOLD Limited
F:DUBA
|
0.066x |
|
Shanghai Awinic Technology Co Ltd
SHG:688798
|
0.070x |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
0.057x |
|
OLAM GROUP LTD
F:K25
|
N/A |
|
Bavarian Nordic
CO:BAVA
|
0.098x |
|
SOC.BIC UNS.ADR1/2/EO382
F:BIF0
|
N/A |
Annual Cash Flow Conversion Efficiency for Shenzhen Kangtai Biological Products Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Shenzhen Kangtai Biological Products Co (300601) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥9.66 Billion ≈ $1.41 Billion |
CN¥603.25 Million ≈ $88.27 Million |
0.062x | -42.33% |
| 2023-12-31 | CN¥9.54 Billion ≈ $1.40 Billion |
CN¥1.03 Billion ≈ $151.18 Million |
0.108x | +78.28% |
| 2022-12-31 | CN¥8.99 Billion ≈ $1.31 Billion |
CN¥545.70 Million ≈ $79.85 Million |
0.061x | -66.31% |
| 2021-12-31 | CN¥9.17 Billion ≈ $1.34 Billion |
CN¥1.65 Billion ≈ $241.78 Million |
0.180x | +205.85% |
| 2020-12-31 | CN¥7.46 Billion ≈ $1.09 Billion |
CN¥439.85 Million ≈ $64.36 Million |
0.059x | -67.90% |
| 2019-12-31 | CN¥2.75 Billion ≈ $403.03 Million |
CN¥505.70 Million ≈ $74.00 Million |
0.184x | +0.25% |
| 2018-12-31 | CN¥1.84 Billion ≈ $268.83 Million |
CN¥336.48 Million ≈ $49.24 Million |
0.183x | +27.39% |
| 2017-12-31 | CN¥1.07 Billion ≈ $156.72 Million |
CN¥153.98 Million ≈ $22.53 Million |
0.144x | +34.92% |
| 2016-12-31 | CN¥735.00 Million ≈ $107.55 Million |
CN¥78.32 Million ≈ $11.46 Million |
0.107x | -75.18% |
| 2015-12-31 | CN¥647.12 Million ≈ $94.69 Million |
CN¥277.85 Million ≈ $40.66 Million |
0.429x | +123.70% |
| 2014-12-31 | CN¥583.81 Million ≈ $85.43 Million |
CN¥112.06 Million ≈ $16.40 Million |
0.192x | +170.74% |
| 2013-12-31 | CN¥372.17 Million ≈ $54.46 Million |
CN¥26.38 Million ≈ $3.86 Million |
0.071x | +482.01% |
| 2012-12-31 | CN¥431.21 Million ≈ $63.10 Million |
CN¥5.25 Million ≈ $768.62K |
0.012x | -- |
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. The company's marketed vaccines include 13-valent pneumococcal polysaccharide conjugate vaccine, varicella vaccine, freeze-dried, hepatitis B vaccine, inflammatory vaccine, 23-valent pneumococcal polysaccharide vaccine, DTAP/HIB combined vaccine, diphtheria, tetanu… Read more